详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. [2]West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China. [3]Department of Outpatient, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

关键词： cancer inflammation cyclooxygenase non-steroidal anti-inflammatory drugs pharmacogenomics

摘要：

Inflammatory processes are essential for innate immunity and contribute to carcinogenesis in various malignancies, such as colorectal cancer, esophageal cancer and lung cancer. Pharmacotherapies targeting inflammation have the potential to reduce the risk of carcinogenesis and improve therapeutic efficacy of existing anti-cancer treatment. Non-steroidal anti-inflammatory drugs (NSAIDs), comprising a variety of structurally different chemicals that can inhibit cyclooxygenase (COX) enzymes and other COX-independent pathways, are originally used to treat inflammatory diseases, but their preventive and therapeutic potential for cancers have also attracted researchers' attention. Pharmacogenomic variability, including distinct genetic characteristics among different patients, can significantly affect pharmacokinetics and effectiveness of NSAIDs, which might determine the preventive or therapeutic success for cancer patients. Hence, a more comprehensive understanding in pharmacogenomic characteristics of NSAIDs and cancer-related inflammation would provide new insights into this appealing strategy. In this review, the up-to-date advances in clinical and experimental researches targeting cancer-related inflammation with NSAIDs are presented, and the potential of pharmacogenomics are discussed as well.Copyright © 2022 Lai, Liu, Wu, Cai, Jie, Xu and Deng.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区药学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区药学

第一作者：

第一作者机构： [1]Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. [2]West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]塞来昔布抗乳腺癌的临床应用 [2]Nuclear Receptors in Cancer Inflammation and Immunity. [3]乳腺癌相关成纤维细胞：乳腺癌治疗的新靶点 [4]XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers [5]A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy. [6]Managing Cancer Drug Resistance from the Perspective of Inflammation [7]Systemic immune-inflammation index for predicting prognosis of colorectal cancer [8]Association between the Systemic Immune-Inflammation Index and Prostate Cancer [9]Impact of systemic inflammation on gastric cancer outcomes [10]Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs.